Travere Crashed Into Its 200-Day Line And Then Reversed Higher; Here's Why
Shares of Travere Therapeutics took a hit Tuesday, but closed in the green, after fewer than expected patients started taking its drug.
The post Travere Crashed Into Its 200-Day Line And Then Reversed Higher; Here's Why appeared first on Investor's Business Daily .